{ }
UBS CEO Sergio Ermotti highlighted significant overcapacity in the US banking sector during an interview with Lisa Abramowicz on "Bloomberg The Close." He expressed optimism about the US economy, predicting it will continue to outperform the European Union.
23:26 24.10.2024
UBS CEO Sergio Ermotti has expressed concerns that the US banking sector is excessively overcapacitated. UBS Group AG operates through four main businesses: wealth management (54.3% of revenues), investment banking (24.9%), retail and corporate banking (12.3%), and asset management (8.5%). By the end of 2022, the Group is set to manage CHF 525.1 billion in deposits and CHF 387.2 billion in loans, with a geographical income breakdown showing 39.9% from the Americas, 22.3% from Switzerland, and 20.2% from Europe-Middle East-Africa.
23:26 24.10.2024
UBS Group AG operates across four main sectors: wealth management (54.3% of revenues), investment banking (24.9%), retail and corporate banking (12.3%), and asset management (8.5%). As of the end of 2022, the group reported CHF 525.1 billion in current deposits and CHF 387.2 billion in current loans, with significant operating income derived from the Americas (39.9%) and Switzerland (22.3%). CEO Ermotti highlighted concerns about overcapacity in the US banking sector.
23:26 24.10.2024
UBS CEO Ermotti has highlighted significant 'overcapacity' in the US banking sector. UBS Group AG operates across four main areas: wealth management (54.3% of revenues), investment banking (24.9%), retail and corporate banking (12.3%), and asset management (8.5%). As of the end of 2022, the Group reported 525.1 billion Swiss francs in current deposits and 387.2 billion Swiss francs in current loans, with geographical operating income distribution showing 39.9% from the Americas.
23:26 24.10.2024
Investor flows are likely to continue favoring the U.S. over Europe due to differing economic conditions and regulatory environments. Central banks are diversifying away from the dollar, with rising gold prices indicating increased purchases by both private and institutional investors. The fragmented European banking market faces challenges from protectionism, which could hinder innovation and lead to higher borrowing costs, while large banks remain stable despite recent turmoil.
23:06 24.10.2024
UBS CEO Sergio Ermotti announced that the transition of Credit Suisse clients to UBS will take approximately 18 months, following UBS's acquisition of the troubled bank last year. The migration process has begun, with Ermotti emphasizing the complexity and potential benefits of the integration for shareholders, customers, and employees. He also noted that this situation could serve as a valuable case study for regulators evaluating the resolution processes of systemically important banks.
22:03 24.10.2024
Marshall Wace LLP increased its stake in Western Union to 3,337,466 shares, valued at $40.78 million, while M&G Plc entered a new position worth approximately $12.05 million. Analysts have downgraded the stock, with UBS Group setting a target price of $12.00, indicating a potential upside of 8.11%. Western Union's stock recently traded down 3.9% to $11.10, with a market cap of $3.75 billion and a PE ratio of 6.80.
20:40 24.10.2024
UBS has rated Siltronic as 'Neutral' with a target price of €77. The stock closed at €59.95, reflecting a 1.96% increase. Trading activity varied across platforms, with prices reaching €61.95 in Frankfurt and €60.05 in Tradegate.
14:30 24.10.2024
UBS analysts express a "constructive outlook" for global equities, driven by positive US economic data, Chinese stimulus measures, and potential global interest rate cuts. They highlight opportunities in US technology stocks and expect significant growth in Asia ex-Japan and European small- and mid-cap equities.
14:02 24.10.2024
Janus Henderson Group PLC increased its stake in Immunocore to 257,080 shares valued at $16.7 million, while BNP PARIBAS ASSET MANAGEMENT raised its holdings by 16.2% to 397,463 shares worth $13.5 million. Institutional investors own 84.5% of the stock. UBS Group initiated coverage with a "sell" rating and a $24 price target, indicating a potential downside, while other analysts maintain a "Moderate Buy" rating with a consensus target price of $75.17. Immunocore reported a revenue increase of 26.2% year-over-year, with a quarterly earnings per share of ($0.23), surpassing expectations.
13:50 24.10.2024
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.